Logo

AstraZeneca Divests Rights of Seroquel and Seroquel XR to Cheplapharm in Europe and Russia

Share this

AstraZeneca Divests Rights of Seroquel and Seroquel XR to Cheplapharm in Europe and Russia

Shots:

  • AstraZeneca to receive $178M up front and up to $61M as sales-contingent payments while it continues to manufacture and supply Seroquel and Seroquel XR to Cheplapharm during a transition period. The transaction is expected to be closed in Q4’19
  • The divestiture will allow AstraZeneca to focus on its main therapeutic areas by reducing its portfolio of mature medicines
  • Seroquel & Seroquel XR are anti-psychotic therapies with antidepressant properties indicated to treat schizophrenia and bipolar disorder and has generated $47M & $61M revenue in 2018 in EU & Russia

Click here to­ read full press release/ article 

Ref: AstraZeneca | Image: AstraZeneca 


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions